ASX Archives | Page 2 of 3 | Cannabiz

Epsilon posts strongest December quarter following ASX reinstatement

by Adam Sheldon January 28, 2026January 28, 2026

Epsilon Healthcare delivered record December quarter customer receipts of A$2.9 million, up 96% year-on-year, as its […]

Epsilon Healthcare resumes trading on ASX after two-year suspension

by Steve Jones December 19, 2025December 22, 2025

Epsilon working with ASX as two-year suspension deadline approaches

by Adam Sheldon December 9, 2025December 10, 2025

ECS Botanics completes A$1.95m raise to boost product and export plans

by Adam Sheldon November 13, 2025February 21, 2026

Little Green Pharma revenue climbs 10% to $10m in September quarter

by Adam Sheldon October 30, 2025November 3, 2025

News in brief: ASX questions Neurotech over funding; participants sought for endometriosis trial in Sydney

by Adam Sheldon October 29, 2025February 21, 2026

One way or another we’ll list, says Biortica CEO as Bod deadline looms

by Steve Jones September 24, 2025September 24, 2025

‘You can’t be a shrinking violet in this game’: Spring Sciences Australia prepares for IPO to drive expansion

by Steve Jones July 31, 2025July 31, 2025

Althea resumes trading on ASX as board narrowly avoids a second shareholder revolt

by Steve Jones February 3, 2025February 3, 2025

Biortica inches closer to ASX backdoor listing with capital raise set for March

by Steve Jones November 5, 2024April 11, 2025